Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 155 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New insights on self-sampling for cervical cancer screening April 27, 2022 Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in... November 29, 2024 Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... December 17, 2024 ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 Load more HOT NEWS Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate... Struggling Waitress Who Can’t Feed Her 4 Kids After Husband’s Cancer... Woman Uses Passion For Crocheting To Help Cancer Patients, The Homeless... Thinking outside the chromosome – how ecDNA is challenging conventional thinking
